AGIO

Agios Pharmaceuticals, Inc.

27.84

USD

AGIO Earnings Reports

Positive Surprise Ratio

AGIO beat 27 of 40 last estimates.

68%

Next Report

Date of Next Report

Apr 29, 2026

Estimate for Q1 26 (Revenue/ EPS)

$13.90M

-$1.85

Implied change from Q4 25 (Revenue/ EPS)

-30.49%

-0.54%

Implied change from Q1 25 (Revenue/ EPS)

+59.31%

+19.35%

Agios Pharmaceuticals, Inc. earnings per share and revenue

On Feb 12, 2026, AGIO reported earnings of -1.86 USD per share (EPS) for Q4 25, beating the estimate of -1.98 USD, resulting in a 6.31% surprise. Revenue reached 20.00 million, compared to an expected 12.25 million, with a 63.21% difference. The market reacted with a +1.30% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 7 analysts forecast an EPS of -1.85 USD, with revenue projected to reach 13.90 million USD, implying an decrease of -0.54% EPS, and decrease of -30.49% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Corvus Pharmaceuticals, Inc.

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.13

Actual

-$0.15

Surprise

-13.72%

Pharming Group N.V. ADS, each representing 10 ordinary shares

Report Date

Mar 12, 2026 For Q4 25

Estimate

$0.00

Actual

$0.01

Surprise

+16.28%

ADC Therapeutics SA

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.04

Surprise

+85.39%

Kamada Ltd

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.07

Actual

$0.06

Surprise

-24.15%

Allogene Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.22

Actual

-$0.17

Surprise

+22.73%

Molecular Partners AG - ADR

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.32

Surprise

+7.09%

Whitehawk Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.15

Actual

-$0.34

Surprise

-116.42%

Codexis, Inc.

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.04

Actual

$0.11

Surprise

+357.01%

Spruce Biosciences, Inc. Common Stock

Report Date

Apr 13, 2026 For Q4 25

Estimate

-$8.14

Actual

Surprise

Mineralys Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.54

Actual

-$0.40

Surprise

+26.40%

FAQ

What were Agios Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Agios Pharmaceuticals, Inc. reported EPS of -$1.86, beating estimates by 6.31%, and revenue of $20.00M, 63.21% above expectations.

How did the market react to Agios Pharmaceuticals, Inc.'s Q4 2025 earnings?

The stock price moved up 1.3%, changed from $27.71 before the earnings release to $28.07 the day after.

When is Agios Pharmaceuticals, Inc. expected to report next?

The next earning report is scheduled for Apr 29, 2026.

What are the forecasts for Agios Pharmaceuticals, Inc.'s next earnings report?

Based on 7 analysts, Agios Pharmaceuticals, Inc. is expected to report EPS of -$1.85 and revenue of $13.90M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.